InvestSMART

Entropy Neurodynamics Limited (ASX:ENP)

ALERT: Price-sensitive ASX Announcement for ENP
Current share price for ENP : $0.042 0.008 (23.53%)+
Announcement
Release
22 Jul 2026 8:26AM
Price at Release
$0.034
Full Release
download
Summary
Entropy Neurodynamics Limited provided its quarterly activities report and Appendix 4C for the period ended 30 June 2026. The company highlighted significant progress in its TRP-8803 clinical trials, particularly in the treatment of Binge Eating Disorder, demonstrating a 50% remission and 100% clinically meaningful response. Financially, the company reported a net cash usage in operating activities of $1.425 million for the quarter. The company closed the quarter with $5.576 million in cash and equivalents, and $2.6 million in unused financing facilities, indicating a total available funding of $8.176 million. The company also detailed its corporate strategy, including expanding its intellectual property portfolio and advancing regulatory discussions to position TRP-8803 as a next-generation precision psychedelic therapy.
Key Points
  • Entropy Neurodynamics Limited's quarter ended 30 June 2026.
  • TRP-8803 clinical trial showed 50% remission and 100% meaningful response.
  • Net cash used in operating activities was $1.425 million.
  • Ending cash balance was $5.576 million with $8.176 million total funding available.
  • Expansion of intellectual property and regulatory advancements for TRP-8803.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.